Moreover, previous studies have suggested that blocking the PD1 pathway can lead to increased antitumor T‐cell response, and various immunotherapy clinical trials using antibody‐mediated PD1 blockade are underway in patients with various cancers [15]. This evidence concerns the gene PDCD1 and cancer.